Shopping Cart 0
Cart Subtotal
USD 0

Galmed Pharmaceuticals Ltd (GLMD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Galmed Pharmaceuticals Ltd (Galmed Pharmaceuticals), a subsidiary of Galmed International Ltd, is a clinical-stage biopharmaceutical company. The company focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Galmed Pharmaceuticals is headquartered in Tel Aviv, Israel.

Galmed Pharmaceuticals Ltd (GLMD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Galmed Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Galmed Pharma Acquires EndoPAT Devices from Itamar Medical for USD0.7 Million 11

Partnerships 12

Galmed Pharma Enters into Agreement with University of California 12

Galmed Pharma Enters into Research Agreement with Yeda Research and Development 13

Galmed Pharma Forms Partnership with Icahn School of Medicine at Mount Sinai 14

Licensing Agreements 15

Samil Pharma Enters into Licensing Agreement with Galmed Pharma for Aramchol 15

Equity Offering 16

Galmed Pharma Prices Public Offering of Shares for USD75 Million 16

Galmed Pharma Prices Direct Offering of Shares for USD6 Million 18

Galmed Pharma Raises USD11.6 Million in Public Offering of Shares 19

Galmed Pharma Prices Private Placement of Shares for USD2.4 Million 20

Galmed Pharma Prices Private Placement of Shares for USD0.4 Million 21

Galmed Pharma Raises USD4.8 Million in Public Offering of Shares 22

One Way Liver Genomics to Raise USD0.2 Million in Financing Round 23

Galmed Pharma Completes IPO For USD 44 Million 24

Galmed Pharmaceuticals Ltd-Key Competitors 26

Galmed Pharmaceuticals Ltd-Key Employees 27

Galmed Pharmaceuticals Ltd-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Nov 05, 2018: Galmed Pharmaceuticals provides business update and reports third quarter 2018 financial results 29

May 09, 2018: Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results 30

Nov 09, 2017: Galmed Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update 31

Jul 31, 2017: Galmed Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 32

May 15, 2017: Galmed Pharmaceuticals Reports First Quarter 2017 Financial Results 33

Mar 23, 2017: Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results 34

Corporate Communications 36

Jun 08, 2017: Galmed Pharmaceuticals Announces the Election of Dr. Carol L. Brosgart as a New Member of the Board of Directors 36

Legal and Regulatory 37

Feb 07, 2018: Galmed Granted "Preferred Technological Enterprise" Status Which may Provide the Company With Significant Financial Benefits 37

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38


List Of Figure

List of Figures

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Galmed Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Galmed Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Galmed Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Galmed Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Galmed Pharma Acquires EndoPAT Devices from Itamar Medical for USD0.7 Million 11

Galmed Pharma Enters into Agreement with University of California 12

Galmed Pharma Enters into Research Agreement with Yeda Research and Development 13

Galmed Pharma Forms Partnership with Icahn School of Medicine at Mount Sinai 14

Samil Pharma Enters into Licensing Agreement with Galmed Pharma for Aramchol 15

Galmed Pharma Prices Public Offering of Shares for USD75 Million 16

Galmed Pharma Prices Direct Offering of Shares for USD6 Million 18

Galmed Pharma Raises USD11.6 Million in Public Offering of Shares 19

Galmed Pharma Prices Private Placement of Shares for USD2.4 Million 20

Galmed Pharma Prices Private Placement of Shares for USD0.4 Million 21

Galmed Pharma Raises USD4.8 Million in Public Offering of Shares 22

One Way Liver Genomics to Raise USD0.2 Million in Financing Round 23

Galmed Pharma Completes IPO For USD 44 Million 24

Galmed Pharmaceuticals Ltd, Key Competitors 26

Galmed Pharmaceuticals Ltd, Key Employees 27

Galmed Pharmaceuticals Ltd, Subsidiaries 28

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Galmed Pharmaceuticals Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.